Viewing Study NCT02588261

Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug

Ignite Creation Date: 2025-12-24 @ 12:02 PM

Ignite Modification Date: 2026-01-25 @ 3:56 AM

Study NCT ID: NCT02588261

Status: TERMINATED

Last Update Posted: 2024-12-10

First Post: 2015-10-26

Is Gene Therapy: True

Has Adverse Events: True

Brief Title: A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations

Sponsor: Astellas Pharma Global Development, Inc.

Organization:

Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module Adverse Events Module Baseline Characteristics Module Participant Flow Module